Clinical trials: High-risk Localized Prostate Cancer
Prostate Cancer
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00033631
- Testing
- 70.2 Gy 3D-CRT/IMRT, 79.2 Gy 3D-CRT/IMRT
- Where
- 86 sites in United States, Canada
- Volunteers
- 1,534 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004054
- Testing
- bicalutamide, estramustine phosphate sodium, etoposide
- Where
- 54 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.
- Trial name
- NCT00860158
- Testing
- Dasatinib, Leuprolide Acetate (LHRH Analogue), Radical Prostatectomy
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Noah Hahn, M.D.
Cancer
Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
This study is for patients who have a high risk of metastatic prostate cancer (cancer that has spread outside of the prostate) who are going to have radical prostatectomy.
- Trial name
- EDRN-FACBC (NCT03081884)
- Testing
- FACBC PET-CT Imaging
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Emory University
Prostate Cancer
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
The purpose of this study is to evaluate safety and efficacy of abiraterone acetate plus leuprolide acetate and prednisone, versus leuprolide acetate alone in male participants with prostate cancer (a disease in which cells in…
- Trial name
- NCT00924469
- Testing
- Abiraterone, Leuprolide, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
The study is being done to find out whether combining two FDA approved drugs along with radiation therapy for the treatment of high risk localized prostate cancer is safe and well tolerated.
- Trial name
- NCT02064582
- Testing
- Enzalutamide, Leuprolide acetate, radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy 2-8 weeks after completion(standard of care and not a part of study)
- Trial name
- NCT00828308
- Testing
- Ixabepilone, Prostatectomy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Brown University
Prostate Cancer
The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer
Silibinin has demonstrated anti-cancer activity in the laboratory for several different cancer types, including prostate cancer. Silibinin was originally obtained from milk thistle.
- Trial name
- NCT00487721
- Testing
- Silibin-Phytosome
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Colorado, Denver
Prostatic Neoplasms, Genital Neoplasms, Male
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-PSMA PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI…
- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
- Trial name
- NCT04461509
- Testing
- 18F-PSMA
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Alessandro D'Agnolo
Prostate Cancer Adenocarcinoma in Situ
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to…
- Trial name
- NCT01696877
- Testing
- degarelix acetate, Cyclophosphamide, GVAX
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer.
- Trial name
- NCT00116142
- Testing
- Docetaxel, Androgen Hormonal Suppression and Radiation, Androgen Suppression Therapy and Radiation Therapy
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00321698
- Testing
- Intensity-Modulated Radiation Therapy (IMRT), Docetaxel+IMRT
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be administered at the same time as standard treatment, which includes hormonal therapy and external beam radiotherapy.
- Trial name
- NCT00924807
- Testing
- Leuprolide acetate, Bicalutamide, Sorafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Beth Israel Medical Center
Prostate Cancer
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
This study evaluates the safety, anti-tumor effect, and immunogenicity of Enoblituzumab given before radical prostatectomy. All patients will receive Enoblituzumab for 6 weekly doses beginning 50 days prior to radical…
- Trial name
- NCT02923180
- Testing
- Enoblituzumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
Primary Objective: 1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1.
- Trial name
- NCT00500110
- Testing
- Docetaxel, Imatinib Mesylate, Leuprolide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Adenocarcinoma
Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
The present study is a phase III randomized and multicentric trial evaluating the potential additional impact effect of two years adjuvant androgen deprivation when combined with neoadjuvant (4 months) and high-dose (76 Gy)…
- Trial name
- AADLPC (NCT02175212)
- Testing
- Short term androgen deprivation, Long term androgen deprivation
- Where
- Spain
- Volunteers
- 362 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Prostate Cancer
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
This is a single-center, single arm, open-label phase II study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical prostatectomy.
- Trial name
- NCT03886493
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Adenocarcinoma
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
The primary objective of this study is to document the effectiveness of Cyberknife stereotactic body radiotherapy (SBRT) in the treatment of intermediate and high-risk localized prostate cancer defined by biochemical Disease-Free…
- Trial name
- NCT01985828
- Testing
- CyberKnife, Androgen Deprivation Therapy (ADT), Intensity Modulated radiation therapy (IMRT)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Wake Forest University Health Sciences
Adenocarcinoma of the Prostate, Stage II Prostate Cancer
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
This phase II trial is studying sorafenib tosylate and gene expression in patients undergoing surgery for high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT00466752
- Testing
- sorafenib tosylate, microarray analysis, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
High-Dose Stereotactic Radiation for Prostate Cancer
This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01664130
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center